Christina Ohnsman

Christina Ohnsman

Company: REGENXBIO

Job title: Senior Clinical Development Lead

Bio:

Christina Ohnsman, MD is a Senior Clinical Development Lead at REGENXBIO Inc., a leading gene therapy biopharmaceutical company based in Rockville, Maryland.  Dr. Ohnsman has 20+ years of experience as a pediatric ophthalmologist in private practice and on the faculty at Wills Eye Hospital.  Later in her career, she founded and led a medical communications and consulting company, providing strategic guidance and content for scientific presentations, publications, medical education initiatives, and clinical messaging. She has worked closely with various biotechnology, pharmaceutical, and device companies in the fields of ophthalmology, gene therapy, and rare diseases, including Spark Therapeutics, supporting the late development and launch of LUXTURNA, FDA’s first approved gene therapy for a genetic disease. In her role at REGENXBIO, Dr. Ohnsman is responsible for leading the clinical development of investigational gene therapies for rare ocular indications. She remains dedicated to her consistent, passionate focus on improving patients’ lives.

Seminars:

Creating a Bespoke Endpoint That is Meaningful to the Patient 9:30 am

• Beyond visual acuity: developing endpoints that are meaningful to patients and regulatory bodies • Measuring functional vision vs. visual function • The role of patient-reported outcome measures • Designing and validating novel endpointsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.